NASDAQ: CRMDCormedix Inc Stock
$7.67+0.15 (+1.99%)
Updated Apr 17, 2025
CRMD Price
$7.67
Fair Value Price
-$0.28
Market Cap
$499.94M
52 Week Low
$3.61
52 Week High
$13.85
P/E
-25.57x
P/B
5.91x
P/S
10.97x
PEG
N/A
Dividend Yield
N/A
Revenue
$43.47M
Earnings
-$17.93M
Gross Margin
92.7%
Operating Margin
-44.37%
Profit Margin
-41.2%
Debt to Equity
0.4
Operating Cash Flow
-$51M
Beta
1.11
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CRMD Overview
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRMD's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CRMD
Ranked#11 of 463
Ranked#11 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important CRMD news, forecast changes, insider trades & much more!
CRMD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRMD ($7.67) is overvalued by 2,885.25% relative to our estimate of its Fair Value price of -$0.28 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRMD ($7.67) is not significantly undervalued (2,885.25%) relative to our estimate of its Fair Value price of -$0.28 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRMD due diligence checks available for Premium users.
Valuation
CRMD fair value
Fair Value of CRMD stock based on Discounted Cash Flow (DCF)
Price
$7.67
Fair Value
-$0.28
Undervalued by
2,885.25%
CRMD ($7.67) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRMD ($7.67) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CRMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-25.57x
Industry
-177.72x
Market
27.98x
CRMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.91x
Industry
4.05x
CRMD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRMD's financial health
Profit margin
Revenue
$31.2M
Net Income
$13.5M
Profit Margin
43.1%
CRMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CRMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$118.8M
Liabilities
$34.2M
Debt to equity
0.4
CRMD's short-term assets ($114.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRMD's short-term assets ($114.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRMD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CRMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.6M
Investing
-$304.2k
Financing
$11.3M
CRMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRMD vs Biotech Stocks
Cormedix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.